The Market Signal was created as a platform to help investors, if you own (NASDAQ:IDEX), (NASDAQ:INO) or (NASDAQ:INTC) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.
https://themarketsignal.com/Free-Report/NOW
(Click link above or copy, paste and hit enter in your browser for your report)
Ideanomics releases its Q2 2020 financials
https://themarketsignal.com/Free-Report/IDEX
(Click link above or copy, paste and hit enter in your browser for your report)
Ideanomics Inc. (NASDAQ:IDEX) was one of the most popular companies on Robinhood in the past week and it market capitalization as per the latest figures was $302.75 Million.
Ideanomics recently rolled out its Q2 2020 financial report, revealing that its total revenue for the latest quarter was $4.6 million which was significantly lower than the $14.5 million total revenue that the company achieved in Q2 2019. Its gross profit for the three months ended June 30, 2020 was $255,000 compared to $13.7 million in the corresponding quarter in the previous year.
Indeanomics reported a $16.3 million loss from its operations during the latest quarter compared to an operating income of $5.7 million in Q2 2019. The company's net loss for the latest quarter was $26.4 million compared to a net income of $5.2 million in Q2 2019. The company's performance in Q2 2020 was heavily affected by the coronavirus pandemic and the resulting negative impact on business.
Inovio Pharmaceuticals's pursuit of a working vaccine for COVID19
https://themarketsignal.com/Free-Report/INO
(Click link above or copy, paste and hit enter in your browser for your report)
Inovio Pharmaceuticals Inc. (NASDAQ:INO). The company has a market capitalization of $2.05 Billion and is currently one of the most popular stocks on Robinhood.
Inovio Pharmaceuticals is one of the companies that have collaborated with Chinese companies to test their coronavirus vaccines in the country. Inovio has particularly made significant strides forward with its developmental treatments for combatting the coronavirus. The company has been developing a DNA-based vaccine for SARS-CoV2. The company reported at the end of July this year that its treatment for respiratory tract disorder received orphan drug destination from the FDA. The treatment is called INO-3107 and it is a DNA treatment that targets recurrent respiratory papillomatosis, a rare illness triggered by human papillomavirus types 6 and 11 infections.
Intel to integrate Foveros 3D into its future 7nm FPGA products
https://themarketsignal.com/Free-Report/INTC
(Click link above or copy, paste and hit enter in your browser for your report)
Intel Corporation (NASDAQ:INTC) had a market capitalization of $214.33 Billion by the end of the latest trading session and it is one of the companies in the list of most popular Robinhood stocks.
Intel revealed during its Architecture Day 2020 that it will equip future FPGA products with three new advanced packaging solutions that include ODI, Foveros 3D and EMIB. Intel introduced Foveros as its die-to-die '3D' stacking solution that makes it possible for two bits of silicon to be connected through one EMIB. The advantage to this approach is that it facilitates low-power and rapid point-to-point connections. The company currently uses Foveros in its Lakefield mobile processor. It will also be available in products such as Ponte Vecchio which will be launched in the future, and also in FPGAs.
Please email or contact us for any edits or errors relating to this stock market news.
If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.
We will get back to you within 24 hours.
COMTEX_370468043/2700/2020-09-01T06:53:26
Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.
